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Abstract
Background—The purpose of this study was to enhance the current understanding and 
interpretation of longitudinal change on tests of neurocognitive function in individuals with 
cancer. Scores on standard neuropsychological instruments may be impacted by practice effects 
and other random forms of error.
Methods—The current study assessed the test–retest reliability of several tests and overarching 
cognitive domains comprising a neurocognitive battery typical of those used for research and 
clinical evaluation using relevant time frames. Practice effect-adjusted reliable change confidence 
intervals for test–retest difference scores based on a sample of patient-matched healthy controls 
are provided.
Results—By applying reliable change confidence intervals to scores from two samples of breast 
cancer patients at post-treatment follow-up assessment, meaningful levels of detectable change in 
cognitive functioning in breast cancer survivors were ascertained and indicate that standardized 
neuropsychological instruments may be subject to limitations in detection of subtle cognitive 
dysfunction over clinically relevant intervals, especially in patient samples with average to above 
average range baseline functioning.
Conclusions—These results are discussed in relation to reported prevalence of cognitive change 
in breast cancer patients along with recommendations for study designs that enhance detection of 
treatment effects.
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Introduction
A growing body of research has provided evidence for cognitive change associated with 
adjuvant treatment for breast cancer [1]. However, inconsistencies remain, including widely 
varying prevalence rates (i.e., 0–77% post-treatment impairment), higher prevalence rates 
based on patient self-report compared with objective neuropsychological assessments, and 
discrepancies in the level of severity of cognitive change (i.e., survivor reports of inability to 
return to work or school versus relatively subtle or absent changes based on 
neuropsychological test performance). Variability in prevalence has been attributed to 
differences in study design, test batteries used, variation in treatment regimens, and 
differences in sample characteristics. Self-report of cognitive function has also been 
questioned due to the influence of psychological factors, such as depression and anxiety. 
However, another source of variation may relate to basic psychometric properties of 
neuropsychological tests and their sensitivity to detecting relatively subtle change, 
particularly within the normal range of cognitive function.
The standardized neuropsychological instruments commonly used to measure cognitive 
change in individuals with cancer are often those developed originally to determine lesion 
location and impairment in patients with overt neurological injuries and illnesses, such as 
traumatic brain injury or degenerative dementing conditions. The degree of impairment 
accompanying these conditions is often severe [2,3], particularly compared with 
neurocognitive effects expected following cancer treatment. Further, test–retest reliability 
data for many of these measures are only available for shorter durations (e.g., 1–3 weeks), 
and only limited data exist over more extended time frames of greater clinical or research 
relevance to cancer patients (e.g., 6 or more months). However, the potential implications of 
measurement-related error for the use of these measures in research and clinical evaluation 
of cancer-related cognitive decline have been largely unexplored in the cancer context. That 
is, the use of these same neuropsychological instruments in cancer-treated samples may be 
limited because of the test–retest reliability as well as ceiling effects, restricted range of test 
scores, and low sensitivity in samples with average range (or above) premorbid cognitive 
abilities and potentially subtle cognitive changes [4].
The purpose of this study was therefore two-fold. Because scores on standard 
neuropsychological instruments may be impacted by several factors, including true changes 
in performance, practice effects, regression towards the mean, and random measurement 
error, interpretation of change involves acknowledgment of the full range of measurement 
error for each test–retest difference interval. We first sought to assess the test–retest 
reliability of several tests comprising a neurocognitive battery typical of those used for 
research and clinical evaluation using time frames typical of longitudinal research studies 
and to provide reliable change confidence intervals for test–retest difference scores based on 
a sample of patient-matched healthy controls. Second, we sought to enhance the current 
understanding and interpretation of longitudinal change on tests of neurocognitive function 
in individuals with breast cancer. In order to examine effects of site, treatment type, and 
test–retest interval, we present analyses for two samples of patients and matched controls, 
one collected as part of a US study involving patients receiving chemotherapy and another 
collected as part of a study of endocrine therapy at a site in the Netherlands. By applying 
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reliable change confidence intervals to scores from these two samples of breast cancer 
patients at post-treatment follow-up assessment, meaningful levels of detectable change in 
cognitive functioning in breast cancer survivors were ascertained and are discussed in 
relation to reported prevalence of cognitive change in breast cancer patients.
Methods
Patients
Sample 1—Eligible patients were newly diagnosed patients with breast cancer recruited 
from the Breast Cancer Service of the Dartmouth-Hitchcock Norris Cotton Cancer Center as 
part of a longitudinal study of cognitive change in breast cancer survivors exposed to 
chemotherapy. Extended data on inclusion/exclusion criteria for study participation as well 
as sample characteristics have been described elsewhere [5]. Briefly, patients (n=60) were 
eligible for participation if they were diagnosed with noninvasive (stage 0) or invasive (stage 
1, 2, or 3A) breast cancer, undergoing first treatment with systemic chemotherapy, between 
18 and 70 years of age at time of diagnosis, and fluent in English and able to read English. 
Patients were excluded on the basis of the following criteria: central nervous system (CNS) 
disease; previous history of cancer (except basal cell carcinoma) or treatment with 
chemotherapy, CNS radiation, or intrathecal therapy; neurobehavioral risk factors, including 
history of neurologic disorder (e.g., Parkinson’s disease, seizure disorder, and dementia), 
alcohol/substance abuse, or moderate to severe head trauma (loss of consciousness >60 min 
or structural brain changes on imaging); or Axis I psychiatric disorder (according to the 
Diagnostic and Statistical Manual of Mental Disorders, ed 4 [DSM-IV]; (e.g., schizophrenia, 
bipolar disorder, and depression).
Female healthy controls (n=45) who met the same inclusion (except for cancer diagnosis) 
and exclusion criteria were recruited through community advertisements. Healthy controls 
were frequency matched to patients on age and education. All methods and procedures were 
approved by the institutional review board of Dartmouth Medical School, and all 
participants provided written informed consent.
For patients, the pretreatment assessment occurred after surgery but before initiation of 
adjuvant therapy. Follow-up assessment for patients treated with chemotherapy was 
conducted 6 months after the baseline assessment, corresponding to approximately 1-month 
post-treatment completion. Because the length of chemotherapy varied, the test–retest 
interval for the follow-up assessment for healthy control participants was frequency matched 
to the interval for the chemotherapy patients. Analysis of the intervals between 
neuropsychological assessments by group revealed no differences. See Table 1 in the 
supporting information for full list of tests in the neuropsychological battery for Sample 1 
[12–17].
Sample 2—Eligible patients were Dutch postmenopausal women participating in the 
tamoxifen exemestane adjuvant multinational (TEAM) trial; an international, open label, 
randomized study comparing the efficacy and safety of 5 years of adjuvant exemestane (25 
mg/d; n=99) with 2.5 to 3 years of tamoxifen (20 mg/d; n=80) followed by 2 to 2.5 years of 
exemestane.
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Additional information on inclusion/exclusion criteria of the TEAM trial as well as sample 
characteristics have been described elsewhere [17]. In short, patients had histologically 
confirmed adenocarcinoma of the breast, positive estrogen and/or progesterone receptor 
status, and had undergone surgery with a curative intent. For this neuropsychological side-
study, additional exclusion criteria included the following: adjuvant chemotherapy, not 
being fluent in the Dutch language, and CNS disease or signs of dementia according to a 
dementia screening tool [18]. In order to take into account the test–retest effects of 
neuropsychological tests, a control group was included that consisted of healthy female 
friends or relatives age-matched to TEAM patients (n=120). Inclusion criteria for controls 
were postmenopausal status, no history of CNS or malignant disease, fluent in the Dutch 
language, and no signs of dementia according to the dementia screening tool. The study was 
approved by the central review board (Erasmus MC, Rotterdam, The Netherlands) and the 
local medical ethics committees of all participating hospitals. All participants provided 
written informed consent.
Initial neuropsychological assessments (T1) were performed after definite breast surgery, 
and immediately before the start of adjuvant endocrine treatment. This point in time was 
chosen in order to minimize potential effects of other treatments on cognition in the interval 
between T1 and T2. Follow-up assessments were conducted 1 year after the baseline 
assessment (T2). Healthy control participants underwent the same assessments with a 
similar time interval of 1 year. See Table 1 in the supporting information for full list of tests 
in neuropsychological battery for Sample 2 [15,18–25].
Statistical analysis
Descriptive statistics were calculated for the healthy control group for each test in the 
neuropsychological battery at baseline and follow-up time points and are presented in Tables 
1 and 2. The descriptive statistics for the healthy control samples were used to calculate 
reliable change confidence intervals based on the procedure described by Jacobson and 
Truax [6]. According to this procedure, the standard error of measurement (SEM) from each 
of the baseline (SEM1) and follow-up (SEM2) testing sessions and the standard error of the 
difference (SEdiff) were used to compute the reliable change confidence intervals based on 
the following equation:
Paired sample t-tests were then used to calculate repeat testing effects in each group, 
accounting for score improvement because of practice and procedural learning. For tests 
exhibiting significant repeat testing effects (p=< 0.05), mean improvements in the healthy 
control group were added to the confidence intervals.
These reliable change intervals were then applied to the patient and healthy control samples 
to determine the percentage of patients and controls that declined at both 80% and 95% 
confidence intervals. This procedure has been used in previous studies assessing sensitivity 
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of cognitive measures in novel populations (e.g., concussion [7], dementia [8], and cognitive 
status in the elderly [9]).
Results
Test–retest reliability
Pearson correlations indicating test–retest reliability between baseline and follow-up 
assessments for the healthy control groups of Samples 1 and 2 are shown in Tables 1 and 2 
at the individual test and domain levels. For Sample 1, test–retest reliability at the level of 
individual measures ranged from 0.23 to 0.90 (mean=0.67) and from 0.64 to 0.89 
(mean=0.74) at the domain level. For Sample 2, test–retest reliability at the level of 
individual measures ranged from 0.57 to 0.88 (mean=0.74) and from 0.60 to 0.89 
(mean=0.80) at the domain level.
Longitudinal change in performance
As shown in Table 1, the healthy control group in Sample 1 exhibited significant 
improvement on several measures (i.e., Digit Symbol-Coding, Logical Memory I & II, Faces 
I & II, CVLT Total Trials 1–5, CVLT Long Delay Recall, CPT Vigilance Total Correct, 
Trail Making 3, Trail Making 4, and Trail Making 5) between the baseline and follow-up 
assessments (p<0.05). As shown in Table 2, the healthy control group in Sample 2 exhibited 
significant improvement on selected tests (i.e., RAVLT Delayed Recall, Visual Association 
Test) between the baseline and follow-up assessments (p<0.05).
Reliable change
Reliable change confidence intervals are presented in Tables 1 and 2 and include calculated 
practice effects for tests, which showed a significant performance improvement from 
baseline to follow-up assessments. Effect sizes (i.e., Cohen’s Delta) are also presented in 
Tables 1 and 2 as a standardized metric signifying the magnitude of change for each 
interval. The standardized effect sizes corresponding to the 80% reliable change confidence 
intervals ranged from approximately 0.60 to 1.73 for Sample 1 and from 0.63 to 1.20 for 
Sample 2. The standard effect sizes corresponding to the 95% reliable change confidence 
intervals ranged from approximately 0.91 to 2.40 for Sample 1 and from 0.96 to 1.82 for 
Sample 2. These are considered ‘medium’ to ‘very large’ changes (0.2, small; 0.5, medium; 
0.8, large; 1, very large) [10].
For Sample 1, when the 80% reliable change confidence interval was applied to each 
measure, the percentage of patients indicated as declined ranged from approximately 0% to 
31%, and when the 95% reliable change confidence interval was applied to each measure, 
the percentage of patients indicated as declined ranged from approximately 0% to 22% 
(Table 3). For Sample 2, when the 80% reliable change confidence interval was applied to 
each measure, the percentage of patients indicated as declined ranged from approximately 
4% to 19% for the TMX group and 3% to 15% for the EXE group, and when the 95% 
reliable change confidence interval was applied to each measure, the percentage of patients 
indicated as declined ranged from approximately 0% to 9% for the TMX group and 1% to 
10% for the EXE group (Table 4).
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Discussion
The present study sought to enhance the current understanding and interpretation of 
longitudinal change on tests of neurocognitive function in individuals with cancer. Using 
numerous tests comprising two comprehensive neurocognitive batteries typical of those used 
for research and clinical evaluation of cancer-related cognitive decline over clinically 
relevant (i.e., 6 months and 1 year) time frames, we calculated reliable change indices based 
on 80% and 95% confidence intervals, taking into account any significant practice effects 
for each individual test.
We believe the results of this analysis have implications for the design and analysis of future 
studies of cognitive function in cancer survivors. First, results indicated attenuated test–
retest reliability at longer intervals (i.e., 6 months and 1 year) compared with published 
reliability values during standardization that are derived from shorter intervals (i.e., 1–3 
weeks). Acceptable reliability values for standard neuropsychological measures are 
generally considered at r>/=0.8. In contrast, our analyses of two healthy control samples at 
extended, but perhaps more clinically- or research-relevant intervals, generally fell below 
this value with a subset of measures exhibiting reliability values as low as r= 0.23 to 0.35. 
This finding will have particular importance in detecting subtle cognitive dysfunction typical 
of cancer survivors. In order to detect meaningful cognitive change (i.e., the signal), 
differences in test scores will need to exceed the random measurement error inherent in each 
test (i.e., the noise). The range of random variation between time 1 and time 2 in our healthy 
control samples during which no change should be evident (i.e., the effect size from time 1 
to time 2) represents medium to large effects, and treatment-related changes in cancer 
survivors post-treatment is generally expected to be much smaller.
Our results would therefore suggest that these measures could only reliably detect moderate 
to large changes in a given cognitive ability using a sizeable sample over a 6-month or 1-
year time frame, and more subtle changes in ability may thus be lost in the ‘noise’ of a 
measure’s random sources of error. Further, when reliable change intervals were applied to 
patient samples, the percentage of patients exhibiting significant decline was generally lower 
than that of typically self-reported by breast cancer patients. It is of note that these findings 
were observed in two datasets comprised of patients from different assessment sites/
countries (i.e., USA and the Netherlands), receiving different cancer treatments (i.e., 
chemotherapy and endocrine therapy), and tested across different intervals (i.e., 6 months 
and 1 year).
Second, single-arm study designs that rely on published test–retest reliability values for 
calculation of a reliable change index may overestimate decline in patient groups. Because 
published test–retest reliability at shorter time points is higher, confidence intervals for 
reliable change that are calculated from published reliability data will be reduced. As a 
result, change in performance over longer time periods that is due to random measurement 
error may be misidentified as true change in performance when relying on published 
reliability values. To address this, we recommend continued accrual of true test–retest 
reliability data at intervals similar to research study time points. More accurate reliable 
change indices can then be calculated for use in studies that collect only patient group 
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cognitive data. Even with this adjustment, however, true change in performance may be 
undetected because of large confidence intervals, and thus collection of a sizeable healthy 
control group may be preferable.
As this may prove burdensome, an alternative approach to overcome the measurement 
challenges we present is the aggregation of tests into cognitive domains. Here, we show that 
relying on confirmatory factor analytic approaches to aggregate individual measures into 
cognitive factor domains by summing standard scores (e.g., z-scores) of individual tests by 
domain can provide greater test–retest reliability and may thus reduce error in measurement 
and provide more accurate indications of decline in this population.
Third, the relation between test reliability and sensitivity may be linked to the specific 
pattern of cognitive dysfunction observed in previous studies of cancer survivors. As 
discussed, a majority of longitudinal studies indicate some degree of post-treatment decline, 
but results suggest that these subtle changes are limited to select cognitive domains. In the 
past, as in the current study, timed measures of psychomotor speed, specifically, have been 
found to be associated with treatment-related effects on cognition [5]. However, our results 
raise the possibility that such findings may be less related to specific patterns of cognitive 
function affected by treatment and, instead, potentially related to increased sensitivity 
resulting from enhanced reliability of psychomotor speed measures. That is, measures of 
psychomotor speed are more reliable and less subject to random ‘noise,’ as exhibited by the 
somewhat smaller effect sizes corresponding to the reliable change confidence interval that 
must be overcome to detect ‘meaningful change’ with a measure.
Lastly, a recent collection of studies suggests more substantial effects in specific high-risk 
subgroups that may currently be moderated by performance improvements because of 
positive practice effects on most standardized instruments in the majority of patients as seen 
in this study. For example, older patients with limited cognitive reserve exposed to 
chemotherapy as well as individuals carrying adverse genetic alleles (e.g., APOE ε4) are 
shown to be at significantly increased risk for post-treatment cognitive decline [5,11]. As 
such, future analyses taking into account sample characteristics are needed to ascertain 
which measures may be most sensitive to detection of treatment effects in vulnerable 
subgroups. Other primary confounds of cognitive function (e.g., sleep and mood) may also 
be assessed at each time point and used as covariates when examining cognitive trajectories 
in survivors.
In summary, neuropsychological measures remain the gold standard in assessing treatment-
related cognitive changes and dysfunction in cancer survivors. Several observations from 
our analysis strongly support changes in study design and methods to improve the sensitivity 
of these measures to the subtle cognitive changes seen in treatment-related dysfunction. 
Chief among these are the importance of establishing reliability values and reliable change 
indices of cognitive measures at clinically meaningful intervals, assessment of practice 
effects at longer intervals to more realistically anticipate changes in performance, collection 
of a control group particularly when this information is not already available, and use of 
aggregate, domain-level performance scores to improve test–retest stability over time.
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